Untitled

Kuwano, Mitsuaki; Ibuki, Hajime; Morikawa, Nobuo; Ota, Atsutoshi; Kawashima, Yasunaru

doi:10.1023/a:1013671819604

Cited by 63 publications

(12 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Propylene glycol is tissue permeation enhancer by supersaturation systems. Kuwano et al demonstrated that CsA solubility into aqueous formulations containing polyoxyl 40 hydrogenated castor oil 23. In an aqueous medium with nonionic surfactant, micelles are formed, allowing CsA to dissolve in them.…”

Section: Discussionmentioning

confidence: 99%

Short Term Effects of Topical Cyclosporine and Viscoelastic on the Ocular Surfaces in Patients with Dry Eye

Moon

Lee

Shin

et al. 2007

Korean J Ophthalmol

View full text Add to dashboard Cite

PurposeTo compare the short term effects of topical 0.05% cyclosporine (CsA) and a mixture of 0.08% chondroitin sulfate and 0.06% sodium hyaluronate (CS-HA) on dry eye ocular surfaces.Methods36 patients with moderate to severe dry eye (5 mm/5 min or less with Schirmer's test or tear break up time (BUT) less than 6 seconds), were treated with topical application of CS-HA on one eye and CsA on the other 4 times a day for 6-8 weeks. BUT, Schirmer's test without anesthesia, and conjunctival impression cytology (CIC; goblet cell density, nucleus to cytoplasmic ratio, and epithelial cell morphology) were evaluated and compared between eyes before and after treatment (repeated measurement of ANOVA).ResultsAfter treatment, BUT and tear wettings were significantly prolonged in each group. Topical CsA treated eyes had greater increase in BUT (p=0.026); there was no significant difference in tear wetting (p=0.132). While the 3 parameters of CIC improved in both groups, goblet cell density was significantly higher in eyes treated with CsA (p=0.033).ConclusionsWhile both CS-HA and 0.05% CsA eyedrops improve ocular surfaces, topical CsA may have a better effect on enhancing tear film stability and goblet cell density.

show abstract

Section: Discussionmentioning

confidence: 99%

Short Term Effects of Topical Cyclosporine and Viscoelastic on the Ocular Surfaces in Patients with Dry Eye

Moon

Lee

Shin

et al. 2007

Korean J Ophthalmol

View full text Add to dashboard Cite

show abstract

“…CsA is a lipophilic endecapeptide drug used as an immuno-suppressive agent in the treatment of severe inflammatory and immune-related ocular diseases (Kuwano et al, 2002). However, because of its poor water-solubility, CsA is commonly formulated as solution in oil, which would lead to poorly tolerated ocular irritation when topically applied (De Campos et al, 2001).…”

Section: Original Articlementioning

confidence: 99%

Low molecular weight chitosan-coated liposomes for ocular drug delivery:In vitroandin vivostudies

Li¹,

Zhuang²,

Wang³

et al. 2011

Drug Delivery

View full text Add to dashboard Cite

“…An ideal topical formulation to the eye must fulfill several requirements as follows: the formulation must be well tolerated and easy to administer, increase CsA retention time in the eye, and avoid systemic absorption. Various ophthalmic formulations have been developed to improve ocular penetration, reduce toxicity, and improve tolerability of CsA [26, 27]. …”

Section: Introductionmentioning

confidence: 99%

An Overview on Dry Eye Treatment: Approaches for Cyclosporin A Delivery

Yavuz

Pehlivan

Ünlü

2012

The Scientific World Journal

View full text Add to dashboard Cite

Dry eye syndrome (DES, Keratoconjunctivitis sicca) is a common disorder of the tear film caused by decreased tear production or increased evaporation. Changes in tear composition also promote inflammation on the ocular surface by various mechanisms. Artificial tear drops, tear retention treatment, stimulation of tear secretion, or anti-inflammatory drugs may be used for dry eye treatment according to the severity of the disease. For untreated patients, the risk of ocular infection increases at considerable level and clinical course of the disease may proceed up to infection, corneal ulcer, and blindness. Artificial tears and/or punctual occlusions are used for tear replacement or preservation. New treatment approaches are designed to modify the underlying disease process. For the treatment of severe dry eye disease, cyclosporin A (CsA), the first one of the new generation immunomodulatory drugs, which has an anti-inflammatory effect, is frequently used. CsA has immunosuppressive effects following systemic application. Following local administration of CsA, it is expected to obtain effective drug concentration at the target area and to avoid the various side effects associated with systemic delivery. Microspheres, implants, and liposomes have been developed for administration of CsA subconjunctivally in order to enhance its efficiency.

show abstract

Untitled

Cited by 63 publications

References 3 publications

Short Term Effects of Topical Cyclosporine and Viscoelastic on the Ocular Surfaces in Patients with Dry Eye

Short Term Effects of Topical Cyclosporine and Viscoelastic on the Ocular Surfaces in Patients with Dry Eye

Low molecular weight chitosan-coated liposomes for ocular drug delivery:In vitroandin vivostudies

An Overview on Dry Eye Treatment: Approaches for Cyclosporin A Delivery

Contact Info

Product

Resources

About